OMT-28
Atrial Fibrillation
Key Facts
About OMEICOS Therapeutics
OMEICOS Therapeutics is a private, clinical-stage biotech leveraging proprietary science in omega-3 fatty acid metabolism to develop novel small molecules. Its lead asset, OMT-28, targets inflammation and mitochondrial dysfunction and has successfully completed a Phase 2 trial in atrial fibrillation, showing safety and positive biomarker modulation. The company is now advancing OMT-28 into a Phase 2 proof-of-concept study in primary mitochondrial diseases and planning a study in coronary artery disease, positioning it in large, underserved therapeutic markets.
View full company profileAbout OMEICOS Therapeutics
OMEICOS Therapeutics is a private, clinical-stage biotech leveraging proprietary science in omega-3 fatty acid metabolism to develop novel small molecules. Its lead asset, OMT-28, targets inflammation and mitochondrial dysfunction and has successfully completed a Phase 2 trial in atrial fibrillation, showing safety and positive biomarker modulation. The company is now advancing OMT-28 into a Phase 2 proof-of-concept study in primary mitochondrial diseases and planning a study in coronary artery disease, positioning it in large, underserved therapeutic markets.
View full company profileAbout OMEICOS Therapeutics
OMEICOS Therapeutics is a private, clinical-stage biotech leveraging proprietary science in omega-3 fatty acid metabolism to develop novel small molecules. Its lead asset, OMT-28, targets inflammation and mitochondrial dysfunction and has successfully completed a Phase 2 trial in atrial fibrillation, showing safety and positive biomarker modulation. The company is now advancing OMT-28 into a Phase 2 proof-of-concept study in primary mitochondrial diseases and planning a study in coronary artery disease, positioning it in large, underserved therapeutic markets.
View full company profileTherapeutic Areas
Other Atrial Fibrillation Drugs
| Drug | Company | Phase |
|---|---|---|
| Non-viral gene therapy for Atrial Fibrillation | Inomagen Therapeutics | Pre-clinical |
| AP31969 | Acesion Pharma | Phase 2 |
| Budiodarone | XYRA | Phase 2 |
| Echomplish AF Ablation System | Healium Medical | Preclinical |
| FARAPULSE PFA System | Boston Scientific | FDA Approved |